You are here : Home / Funding Opportunities

Funding Opportunities

Funding Opportunities

JANUARY 2020 FUNDING OPPORTUNITY

 

  • Treating Diabetes Distress to Improve Glycemic Outcomes in Type 1 Diabetes (R01 Clinical Trial Required)

 Management of type 1 diabetes (T1D) requires a complex regimen of blood glucose monitoring, medication dosing, and adjustments in diet and physical activity to achieve tight glucose control while avoiding hypoglycemia. These constant self-management demands, as well as fear of complications, are associated with diabetes distress, a negative emotional response to the chronic burden of living with T1D. Diabetes distress is very common in individuals with T1D and is distinct from psychological disorders such as depression. Diabetes distress may significantly impact medication taking and other self-care behaviors and has been linked to higher HbA1c. Parents of children with type 1 diabetes, as well as partners of individuals with type 1 diabetes, may also experience diabetes distress, sometimes stemming from perceptions of guilt, which may adversely impact their ability to provide management support for their child or partner.

There is growing awareness of the importance of patient-reported outcomes (PROs), including diabetes distress, in the management of T1D. PROs complement biomedical outcomes by capturing patient experiences with disease management beyond that measured by a biomedical assay, such as HbA1c. Recently, clinical care guidelines have emphasized the importance of assessing and addressing psychosocial care as a critical and integral part of the treatment of individuals with diabetes. Such guidelines include the recommendation that individuals with diabetes should be monitored for diabetes distress at medical appointments and be referred for enhanced diabetes education or behavioral counseling, especially when self-care is suboptimal. The most efficacious and cost-effective approaches for ameliorating diabetes distress have not been determined.

 

Link: https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-19-021.html

Application Date Line: March 26, 2020

All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s).

Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

  • Discovery of Early Type 1 Diabetes Disease Processes in the Human Pancreas [HIRN Consortium on Beta Cell Death and Survival (CBDS)] (U01 Clinical Trial Not Allowed)

This Funding Opportunity Announcement (FOA) requests applications to explore human pancreatic tissues for the discovery of specific signaling or processing pathways that may contribute to the asymptomatic phase of T1D, the discovery of early biomarkers of T1D pathogenesis, the development of diagnostic tools for the detection and staging of early T1D in at-risk or recently-diagnosed individuals, and/or the identification and biological validation of therapeutic targets for the development of preventative or early treatment strategies. Successful applicants will join the Consortium on Beta Cell Death and Survival (CBDS), whose mission is to better define and detect the mechanisms of beta cell stress and destruction central to the development of T1D in humans, with­ the long-term goal of protecting the residual beta cell mass in T1D patients as early as possible in the disease process, and of preventing the progression to autoimmunity. The CBDS is part of a collaborative research framework, the Human Islet Research Network (HIRN, https://hirnetwork.org/), whose overall mission is to support innovative and collaborative translational research to understand how human beta cells are lost in T1D, and to find innovative strategies to protect and replace functional beta cell mass in humans. This FOA will only support studies with a primary focus on increasing our understanding of human disease biology (as opposed to rodent or other animal models). This FOA will not accept applications proposing a clinical trial.

Link: https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-19-024.html

Application Date Line: April 1, 2020

All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s).

Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

 

  • New Investigator Gateway Awards for Collaborative T1D Research (R03 Clinical Trial Not Allowed)

The New Investigator Gateway Award in T1D Research is designed to ensure that a robust pipeline of talented new investigators will continue to embark on successful careers in T1D research. In addition to providing support for preliminary research, the Gateway program provides an opportunity for new Program Directors/Principal Investigators (PD/PIs) to pursue their studies within the intellectual environment of a select number of large, ongoing collaborative research programs. Embedding awardees within an established scientific framework in each of these consortia will provide unique opportunities for New and Early Stage Investigators to increase their understanding of key questions in the field, to network, and to establish unique and potentially long-lasting collaborations that will propel their careers forward. It is anticipated that the Gateway award will provide the support needed to enhance the success of future R01 submissions from New Investigators interested in pursuing careers in T1D research.

Link: https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-19-026.html

Application Date Line: March 25, 2020 and November 3, 2020

All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s).

Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

  • Development and Integration of Novel Components for Open and Closed Loop Hormone Replacement Platforms for T1D Therapy (R01 Clinical Trial Optional)

This Funding Opportunity Announcement (FOA) encourages applications from institutions/organizations proposing original research addressing barriers that limit progress toward effective open- and closed-loop glucose control systems. Proposed research should tackle important obstacles at the level of sensing, hormone formulation and delivery, self-management decision support systems, and/or design of automated controllers/algorithms able to manage an integrated platform. This research may contribute to development of affordable and user friendly technologies to improve glucose control in patients with type 1 diabetes.

Link: https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-19-029.html

Application Date Line: April 7, 2020

All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s).

Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

  • BRAIN Initiative: Biology and Biophysics of Neural Stimulation and Recording Technologies (R01 Clinical Trials Optional)

A central goal of the BRAIN Initiative is to develop new and improved technologies suitable for recording from as well as controlling specified cell types and circuits to modulate and understand function in the central nervous system. In order to accomplish these goals, further information is needed to understand the function of current technologies used for recording or stimulating the nervous system.

This RFA accepts grant applications in two related but distinct areas. The first is to systematically characterize, model, and validate the membrane, cellular, circuit, and adaptive-biological responses of neuronal and non-neuronal cells to various types of stimulation technologies. The second is to understand the biological and bioinformatic content of signals recorded from neuronal and non-neuronal cells and circuits. Development of new technologies, therapies and disease models is outside the scope of this FOA. Activities related to enabling the simultaneous use of multiple recording or stimulation technologies are allowed.

Link: https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-20-006.html

Application Date Line: March 24, 2020, June 2, 2020, October 1, 2020, February 2, 2021, June 1, 2021, October 1, 2021, February 1, 2022, June 1, 2022, and October 3, 2022

by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.

All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s).

Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

  • White Matter Lesion Etiology of Dementia in the U.S. Including in Health Disparity Populations (U19 – Clinical Trial Not Allowed)

Despite established associations between white matter lesions and cognitive impairment including dementia, little prospective information is available to define the characteristics of white matter lesions and associated comorbid clinical factors that cause further cognitive impairment, ultimately resulting in dementia.  This initiative will support one large prospective clinical research study in the U.S. of patients engaged with the health care system because of incidental white matter lesions found on neuroimaging, who present with cognitive complaints, and who thus are at risk for cognitive decline. The goal will be to determine the volume and anatomical features that are both necessary and sufficient to cause cognitive impairment or dementia. The study will include health disparity populations and will examine additional clinical factors and comorbidities, including those along the AD/ADRD spectrum, that may be effect modifiers of the relationship between white matter lesions and cognitive impairment, including dementia. Clinical trial-ready biomarkers of vascular contributions to cognitive impairment and dementia (VCID) should be utilized, further developed, and/or subject to implementation research in this study. Secondary goals include: identifying clinical and mechanistic targets for future VCID interventional trials; determining interrelationships (cross-sectional and longitudinal) among white matter lesions, cerebro- and cardio-vascular disease, and risk factors including dementia-relevant genes. Applicants are encouraged, when scientifically advantageous, to utilize existing resources for VCID research, e.g. MarkVCID, Alzheimer’s Centers, and large NIH-funded prospective cohort studies (e.g. Framingham, ARIC, CHS, NOMAS, etc.) as well as other dementia resources. Given the diverse and complex challenges involved in the design and execution of this study, the award will provide for up to one-year initial protocol refinement and study start-up phase, to be followed by an implementation phase, for a total award period of up to 6 years.

Link: https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-20-013.html

Application Date Line: March 31, 2020

All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s). Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.